Efficacy of Fam-trastuzumab deruxtecan-nxki

A major ongoing study shows that Fam-trastuzumab deruxtecan-nxki can effectively shrink tumors in patients with unresectable or metastatic breast cancer. All patients received two or more HER2-targeted therapies. Of the 184 patients who received trastuzumab at the recommended dose, approximately 61% experienced tumor shrinkage.

Another study involved 524 patients who had previously received HER2-targeted therapy (trastuzumab) and a taxane (taxane) for metastatic or unresectable HER2-positive breast cancer. Studies have shown that patients treated with trastuzumab emtansine lived at least 18.5 months without worsening of their condition, while patients treated with trastuzumab emtansine lived at least 5.6 months. Another major study found that trastuzumab increased the time patients with HER2-low breast cancer lived without their disease worsening. The study involved 557 patients with metastatic or unresectable cancer who had previously been treated with another cancer drug. The study found that patients who received trastuzumab lived an average of 9.9 months without worsening of their condition, compared with 5.1 months for those who received another cancer drug of their doctor's choice.

In a major trial evaluating the efficacy, safety and survival of trastuzumab in HER2m or HER2-expressing non-small cell lung cancer, the primary efficacy outcome measure was confirmed objective response rate (ORR) assessed by blinded independent central review using RECIST v1.1 and duration of response (DOR) in 52 patients in the primary efficacy population. The confirmed ORR was 58% and the median DOR was 8.7 months.

The benefits of trastuzumab in stomach and gastroesophageal cancer were studied in a major study involving 79 patients whose cancer progressed after receiving trastuzumab HER2-targeted therapy. The study did not compare trastuzumab with any other drug or a placebo (dummy treatment). In 42% (33 out of 79 patients) of the cancer patients who responded to the treatment, a reduction in the size of the cancer was observed, lasting an average of 8 months.

Trastuzumab is a new type of injectable anti-cancer drug. Due to its short time on the market, it has not yet entered the scope of medical insurance. It is a strictly controlled drug and its purchase is restricted. Trastuzumab sold in Hong Kong original drug specifications100mg per box may cost more than 10,000 yuan(The price may fluctuate due to the exchange rate). Currently, there are no generic drugs of Trastuzumab on the market. For more specific prices and drug information, please consult the Medical Consultant.